Zika virus constructs and therapeutic compositions thereof

Patent metadata

Field	Value
Publication number	US-12473570-B2
Application number	US-202017609496-A
Country	US
Kind code	B2
Filing date	May 20, 2020
Priority date	May 21, 2019
Publication date	Nov 18, 2025
Grant date	Nov 18, 2025

Abstract

Provided are Zika virus constructs and methods of using Zika virus constructs and Zika viruses to treat subjects in need thereof.

First claim

What is claimed is:

1 . A Zika virus construct comprising a Zika virus genome, wherein said Zika virus genome consists of SEQ ID NO: 7, and wherein said Zika virus construct optionally includes a gene that encodes a mutated E protein comprising SEQ ID NO: 1, wherein the amino acid at position 154 of SEQ ID NO: 1 is any amino acid residue other than asparagine.

2 . The Zika virus construct according to claim 1 , wherein said Zika virus construct comprises (a) the gene that encodes the mutated E protein; (b) a nucleic acid sequence that encodes an immunomodulatory agent; or (c) the gene that encodes the mutated E protein and a nucleic acid sequence that encodes an immunomodulatory agent.

3 . The Zika virus construct according to claim 1 , wherein the amino acid at position 154 of SEQ ID NO: 1 is Thr, His, Asp, Tyr, Ser, Leu, or Lys.

4 . The Zika virus construct according to claim 2 , wherein the amino acid at position 154 of SEQ ID NO: 1 is Thr or Asp.

5 . The Zika virus construct according to claim 2 , wherein the immunomodulatory agent is interleukin 2 (IL2), interleukin 15 (IL15), interleukin 18 (IL18), chemokine (C-C) ligand 5 (CCL5), or tumor necrosis factor superfamily member 14 (TNFSF14).

6 . A pharmaceutical composition comprising, consisting essentially of, or consisting of the Zika virus construct according to claim 1 , and a pharmaceutically acceptable carrier.

7 . The pharmaceutical composition according to claim 6 , wherein the pharmaceutical composition comprises a therapeutically effective amount of the Zika virus construct.

8 . A method of treating a cancer and/or aberrant neuroprogenitor cells in a subject, which comprises administering to the subject one or more Zika virus constructs according to claim 1 and/or a pharmaceutical composition comprising the one or more Zika virus constructs.

9 . The method according to claim 8 , wherein a therapeutically effective amount of the Zika virus construct is administered to the subject by subcutaneous delivery, intravenous delivery, intratumoral delivery, intracerebral delivery, and/or intracarotid delivery.

10 . The method according to claim 8 , wherein the Zika virus construct is administered to the subject at a ratio of about 1:1 to about 10:1 of the cells to be treated or infected by the Zika virus and/or the Zika virus construct.

11 . The method according to claim 8 , wherein the cancer is a glioma, a glioblastoma, a neuroblastoma, or a retinoblastoma.

12 . The Zika virus construct according to claim 2 , wherein the nucleic acid sequence that encodes an immunomodulatory agent is SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.

Assignees

• Univ California

Inventors

• Arumugaswami Vaithilingaraja
• Garcia Jr Gustavo
• Nathanson David A
• Sun Ren

Classifications

• C12N2770/24171

  Demonstrated in vivo effect · CPC title

• C12N2770/24143

  viral genome or elements thereof as genetic vector · CPC title

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2770/24132

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title

• C12N2770/24122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title